NCT02231307

SUBLIVAC FIX Birch Phase III Short-term Efficacy

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Clinical Efficacy and Safety of SUBLIVAC FIX Birch Immunotherapy in Patients Suffering From Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 406 (actual)
• Sponsor: HAL Allergy · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of this phase III study is to asses if SUBLIVAC FIX Birch is safe and effective in reducing birch allergy induced symptoms and birch allergy medication usage.

Conditions

• Birch Pollen Induced Rhinitis/Rhinoconjunctivitis

Interventions

Type	Name	Description
DRUG	SUBLIVAC FIX Birch

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-07-01
• Completion: 2015-11-01
• First posted: 2014-09-04
• Last updated: 2016-09-23

Locations

40 sites across 5 countries: Belgium, Czechia, Germany, Poland, Slovakia